SLC2A1 and pyruvate dehydrogenase deficiency: Over time, the KD has been considered as first choice in the treatment of epilepsy along with specific metabolic disorders, such as Glucose Transporter Protein 1 (GLUT-1) deficiency syndrome and pyruvate dehydrogenase deficiency [98].